Dyspnea; Myocarditis/Pericarditis post receiving 2nd dose of Moderna COVID-19 vaccine; Myocarditis/Pericarditis post receiving 2nd dose of Moderna COVID-19 vaccine; admitted to the hospital with various heart problems; Pain in chest is little different from pain in initial onset; Numbness and tingling in arm; Numbness and tingling in arm; emergency room says that his symptoms currently are related to panic attack; 48 hours later (Sunday) he started feeling worse; Headache; Achiness, bodyache; From his 2nd dose he had typical symptoms of sore throat; Flu like symptoms; This spontaneous case was reported by a consumer and describes the occurrence of CARDIAC DISORDER (admitted to the hospital with various heart problems), DYSPNOEA (Dyspnea), MYOCARDITIS (Myocarditis/Pericarditis post receiving 2nd dose of Moderna COVID-19 vaccine) and PERICARDITIS (Myocarditis/Pericarditis post receiving 2nd dose of Moderna COVID-19 vaccine) in a 22-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-May-2021, the patient experienced FEELING ABNORMAL (48 hours later (Sunday) he started feeling worse). On 03-May-2021, the patient experienced CARDIAC DISORDER (admitted to the hospital with various heart problems) (seriousness criterion hospitalization), MYOCARDITIS (Myocarditis/Pericarditis post receiving 2nd dose of Moderna COVID-19 vaccine) (seriousness criteria hospitalization and medically significant), PERICARDITIS (Myocarditis/Pericarditis post receiving 2nd dose of Moderna COVID-19 vaccine) (seriousness criteria hospitalization and medically significant), PANIC ATTACK (emergency room says that his symptoms currently are related to panic attack), HYPOAESTHESIA (Numbness and tingling in arm) and PARAESTHESIA (Numbness and tingling in arm). In May 2021, the patient experienced OROPHARYNGEAL PAIN (From his 2nd dose he had typical symptoms of sore throat), INFLUENZA LIKE ILLNESS (Flu like symptoms), HEADACHE (Headache) and MYALGIA (Achiness, bodyache). On an unknown date, the patient experienced DYSPNOEA (Dyspnea) (seriousness criterion hospitalization) and CHEST PAIN (Pain in chest is little different from pain in initial onset). The patient was hospitalized on 03-May-2021 due to CARDIAC DISORDER, MYOCARDITIS and PERICARDITIS. At the time of the report, CARDIAC DISORDER (admitted to the hospital with various heart problems), MYOCARDITIS (Myocarditis/Pericarditis post receiving 2nd dose of Moderna COVID-19 vaccine), PERICARDITIS (Myocarditis/Pericarditis post receiving 2nd dose of Moderna COVID-19 vaccine), OROPHARYNGEAL PAIN (From his 2nd dose he had typical symptoms of sore throat), INFLUENZA LIKE ILLNESS (Flu like symptoms), FEELING ABNORMAL (48 hours later (Sunday) he started feeling worse), PANIC ATTACK (emergency room says that his symptoms currently are related to panic attack), CHEST PAIN (Pain in chest is little different from pain in initial onset), HYPOAESTHESIA (Numbness and tingling in arm), PARAESTHESIA (Numbness and tingling in arm), HEADACHE (Headache) and MYALGIA (Achiness, bodyache) had not resolved and DYSPNOEA (Dyspnea) outcome was unknown.            Concomitant products were not provided. Treatment information was not reported.  Patient had tests (results not provided): Electrocardiogram (ECG), cardiac test, cardiac enzymes, ultrasound, cardiac magnetic resonance imaging (MRI), etc).  The patient had no prior history of myocarditis/pericarditis was reported.  It was reported that the patient currently had a different type of numbness.  The caller was not sure about the batch number of 1st dose (02SB21A or 025B21A).  Based on the current available information and temporal association between the use of the product mRNA-1273 and the start date of the events, a causal relationship cannot be excluded. Further information has been requested.   This case was linked to MOD-2021-277706 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 05-Aug-2021: Live follow up information: dose dates and lot number updated.; Sender's Comments: Based on the current available information and temporal association between the use of the product mRNA-1273 and the start date of the events, a causal relationship cannot be excluded. Further information has been requested.